← boothcheck

Is MET overvalued?

boothcheck doesn't label MET overvalued or undervalued and publishes no house fair value, target price, or buy/sell rating. Individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. In the published model solve dated 2026-10-02T07:22:51.515Z, anchored at $94.35, MET is priced for return on equity of 16.9%. The applicable valuation families (asset-based and earnings-power and growth-DCF) land below the price. No applicable model is available for relative-multiple. The report narrative was composed 2026-06-27. The more the price assumes beyond what MetLife, Inc. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from MetLife, Inc.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 27, 2026.

Implied return on equity16.9%
For about—
Held margin (input)—
Margin today—
Price vs asset value1.32x
Price vs earnings power1.67x
Price vs forward growth3.31x
Read the full MET report →
Get boothcheck's read on what MET's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.